Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma

You may be eligible if

• Confirmed diagnosis of melanoma and BRAFV600
• Signed Informed Consent Form
• Unresectable phase III or phase IV melanoma
• The patients should be starting a treatment for melanoma (either first line or subsequent lines)